UNSPSC 51434203: Mefeserpine

This classification denotes an antihypertensive agent with the molecular formula C32H38N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42EL4L295A, chemically known as 3beta,20alpha-yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy-, methyl ester, (p-methoxyphenoxy)acetate (ester) but generally known as mefeserpine, which bears US NIH Compound Identifier 3045407. European Medicines Agency schedules Mefeserpine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08707MIG.

UNSPSC 51434203 Mefeserpine is a Commodity code that encompasses pharmaceutical products supplied to state and local emergency medical services, health agencies, and government healthcare programs. State and local governments procure emergency medications, generic pharmaceuticals, and over-the-counter products under this code for use by fire rescue departments, health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work ranges from spot purchases of specific medication line items with firm expiration and shelf-life requirements to multi-year framework agreements for generic pharmaceuticals distributed through authorized wholesalers. Issuing bodies include city purchasing departments (such as Tampa's), state health agencies (such as Texas HHS), and multistate cooperative purchasing organizations (such as MMCAP administered by Minnesota Department of Administration).

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) on April 24, 2026, due April 8, 2026, for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem vials for Tampa Fire Rescue in Hillsborough County, with an estimated contract value of $40,000 and SLBE sheltered-market designation at 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI (No. HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking direct contracting arrangements outside traditional PBM and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers, with contract effectiveness July 1, 2026, and performance penalties of $200 to $1,500 per violation for compliance failures.